Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reamed and unreamed intramedullary nailing for the treatment of open and closed tibial fractures: a subgroup analysis of randomised trials.

International orthopaedics·2009
Same author

Selective COX-2 inhibitor versus nonselective COX-1 and COX-2 inhibitor in the prevention of heterotopic ossification after total hip arthroplasty: a meta-analysis of randomised trials.

International orthopaedics·2009
Same author

[Study on evaluating sex determining region of the Y as an engrafting track of BMSCs transplantation for repairing osteonecrosis of the femoral head of rabbit].

Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery·2009
Same author

Positive association between benign familial infantile convulsions and LGI4.

Brain & development·2009
Same author

Catalytic enantioselective synthesis of chiral phthalides by efficient reductive cyclization of 2-acylarylcarboxylates under aqueous transfer hydrogenation conditions.

Organic letters·2009
Same author

Significance of urinary liver-fatty acid-binding protein in cardiac catheterization in patients with coronary artery disease.

Internal medicine (Tokyo, Japan)·2009

Related Experiment Video

Updated: Nov 6, 2025

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

14.0K

SARS-CoV-2 replicon for high-throughput antiviral screening.

Qiu-Yan Zhang1,2, Cheng-Lin Deng3, Jing Liu3,4

  • 1The Joint Center of Translational Precision Medicine, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou, 510623, PR China.

The Journal of General Virology
|May 6, 2021
PubMed
Summary

A new SARS-CoV-2 reporter replicon system allows antiviral screening in BSL-2 labs, bypassing the need for live virus manipulation. This safe, high-throughput screening assay accelerates the discovery of effective treatments for severe acute respiratory syndrome coronavirus-2.

Keywords:
SARS-CoV-2antiviral screeningreplicon

More Related Videos

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication
10:16

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication

Published on: October 30, 2021

3.9K
Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses
05:49

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Published on: November 21, 2023

2.1K

Related Experiment Videos

Last Updated: Nov 6, 2025

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

14.0K
High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication
10:16

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication

Published on: October 30, 2021

3.9K
Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses
05:49

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Published on: November 21, 2023

2.1K

Area of Science:

  • Virology
  • Drug Discovery
  • Molecular Biology

Background:

  • Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly pathogenic virus requiring BSL-3 facilities for study.
  • Developing effective antivirals is crucial, but facility limitations hinder research progress.
  • Existing methods for antiviral screening are often constrained by biosafety level requirements.

Purpose of the Study:

  • To develop a safe and efficient reporter replicon system for SARS-CoV-2.
  • To establish a high-throughput screening (HTS) assay for SARS-CoV-2 antiviral discovery in a BSL-2 laboratory.
  • To validate the utility of the replicon-based HTS assay using known inhibitors and natural compounds.

Main Methods:

  • Construction of a SARS-CoV-2 reporter replicon system.
  • Utilizing Renilla luciferase activity to monitor viral transcription and replication.
  • Validation of the replicon system with known antiviral inhibitors.
  • Application of the established HTS assay for screening natural compounds.

Main Results:

  • The reporter replicon system accurately reflects SARS-CoV-2 genome replication levels.
  • The system is suitable for antiviral screening, demonstrating efficacy with known inhibitors.
  • The replicon-based HTS assay was successfully validated with natural compounds.
  • The assay enables SARS-CoV-2 research in a BSL-2 environment, mitigating risks associated with live virus handling.

Conclusions:

  • A novel SARS-CoV-2 reporter replicon system provides a safe platform for antiviral research.
  • The developed HTS assay facilitates efficient screening of potential SARS-CoV-2 therapeutics in BSL-2 laboratories.
  • This approach overcomes facility limitations, accelerating the search for urgently needed SARS-CoV-2 antivirals.